Search results

The identification of country-specific advantages for business activities is one of the most crucial issues of strategic management and international business literatures. We address this issue by examining location-specific conditions for a successful generic medicines industry within 24 European countries. The findings of our fuzzy-set qualitative comparative analysis show that there are no necessary conditions for the high performance or absence of the high-performance industry. By revealing the causal complexity related to the issue, however, we show that the high performance or lack of it results from a configuration of conditions. Specifically, we identify two sufficient causal configurations to both outcomes. These findings provide clear implications for generic medicines industry firms who are planning location choices of their operations. In addition, this study provides a methodological advancement to explain and understand which country elements matter more, for what outcomes, and under what conditions.

Pharmaceutical market value in Iran exceeded to more than US$4bn in 2013, indicating annually over 20 per cent growth. In the past decades, Iranian pharmaceutical industry was supported by government policies, namely, generic substitution, import limitation and local production support; however, the local pharmaceutical manufacturer’s market share in value has been decreased gradually. This study aims to provide historical data on Iran pharmaceutical market to show the importance of new product development to attain greater market share and tries to motivate the pharmaceutical industry located in developing countries to develop more innovative medicines.

This is a descriptive cross-sectional study that investigates the Iranian pharmaceutical market by focusing on new products over a five-year period (2009-2014), and that was augmented by an expert panel to rank subjectively firms’ performance indicators to shed light on the importance of new product development to firms’ performance.

The expert panel results find out that new product development is one of the most important “result indicators” for Iranian pharmaceutical companies. Historically, in line with the experts’ opinion on the new product development, the Iranian pharmaceutical industry has shown its capability to develop new medicines by developing 3,095 new products (mostly new-to-firm) across about 100 firms. Despite this fact, the share of local manufacturers in new medicines’ market decreased from 52 per cent at the beginning of studied period to 24 per cent at the end, and the gap between the unit value of imported and domestically produced medicines has been significantly increased due to low-innovative medicines locally produced.

This research was challenged with limitations such as lack of reliable published data on new medicines in the Iran pharmaceutical market.

This study highlights the fact that developing more innovative products in the generic pharmaceutical industry such as Iran can grant its market share.

This is an original study that shows the effect of innovative product development on market share through historical data.

The purpose of this paper is to defend the appropriateness of a global governance framework for the transnational pharmaceutical corporations (TNPCs) as a way to tackle the problems resulting out of a non‐implementation or violation of the “right to health” by a lack of accessibility of vital medicines in developing countries, and control the risks of the TNPCs themselves and to provide for more accountability and trust on their part. The aim is to show that such a framework can prepare the ground for a win‐win‐situation for all stakeholders and for a sustainable combination of interests in profits, human rights, especially the “right to health”, and human welfare.

This is a conceptual paper on the basis of step‐by‐step analytical and interdiscinplinary approach that requires to pick up arguments from economics, business ethics, law, political science as well as aspects of the human rights and the health governance discourse. A broad spectrum of literature and various information sources are referred to: scientific articles and monographs, newspaper and magazine articles, internet sources and information provided by the corporations themselves and by NGOs (non‐governmental organizations), as well as recent academic and institutional publications. Desk research is the underlying technique to analyze the sources in a heuristic and interpretative way. For a better understanding, first the complexity of the implementation of “the right to health” and the role of different actors will be outlined and second, advantages, positive impacts and deficits of existing health‐related CSR (corporate social responsibility) and multistakeholder initiatives by the TNPCs will be pointed out. This is to prepare a ground for arguing in favor of a global governance framework for the TNPCs and to underline the existence of external and internal drivers for the TNPCs to adhere to a global governance framework.

Especially in developing countries the “right to health” is poorly implemented. TNPCs could contribute to improvements and partly already do so. Yet, the existing approaches are deficitary, insufficient and not sustainable. The problem calls for more accountability in regard to the access to vital medicines. A global governance frameworks for the TNPCs would pose a win‐win‐opportunity: While the TNPCs can benefit from more accountability, precisely defined responsibilities as well as efficiency by constructive, strategic partnerships on a stable level‐playing‐field and a legitimized conduct, their stakeholders benefit from an improved accessibility to vital medicines and an enhanced implementation of the “right to health”.

The paper contributes to the ongoing debate on how to improve the implementation of “right to health” by improving the accessibility of vital medicines, especially in developing (and emerging) countries. It proposes new modes of CSR‐based conduct and partnerships of the TNPCs and a framework of global governance that are urgently required to tackle with a long‐term perspective the problems and threats that pandemics pose on a global scale and to cut down risks for the TNPCs while also widening their markets.

The purpose of this paper is to, the first of its kind, investigate the relationship between the intellectual capital efficiency and organisational performance of the pharmaceutical sector in Bangladesh, an emerging economy that enjoys Trade-Related Aspects of Intellectual Property Rights (TRIPS) relaxation.

The study used hand-picked data from annual reports for five years. The relationship between efficient use of intellectual capital and corporate performance was examined through the practical use of human capital, structural capital and capital employed. Multiple regressions were used to assess their impact on financial performance – specifically, return on assets, return on equity, asset turnover and market-to-book value.

Value-added intellectual coefficient components (i.e. human capital, structural capital and capital employed) significantly explained asset turnover and return on assets but failed to predict the return on equity outcome. Additionally, asset turnover was negatively influenced by structural capital and positively influenced by capital employed. The return on assets was mostly affected by variation in human capital. Intellectual capital did not predict market-to-book value or investment decisions.

This paper provides useful resources for evaluating the financial performance and value creation of companies in emerging economies that enjoy TRIPS exemptions; this research could also be extended using cross-industry comparisons. The findings have theoretical and practical implications, particularly for the pharmaceutical industry in emerging economy contexts, and for managers globally.

This study is among only a few that have reported on the relationship between intellectual capital efficiency and value creation in emerging economy contexts.

The notion of configuration – that the whole is best understood from a systemic perspective and should be viewed as a constellation of interconnected elements – is arguably one of the central ideas of organization studies. Yet, this idea also remains one of the field’s least understood aspects. In this volume and its introduction, we outline a new perspective for understanding configuration. Our starting point is the emergence of set theoretic configurational methods, and especially Qualitative Comparative Analysis (QCA), which provides novel ways for analyzing configurations. Our volume goes beyond introducing a new method to the fields of management and organization, as these methods furthermore offer an opportunity to rethink our understanding of the field and to develop different ways of theorizing the rich complexity of relationships that characterize organizational life. In this introduction, we introduce some of the key themes that differentiate the approach taken here from previous work on organizational configurations and provide evidence for the emerging renaissance of the configurational approach in organizational theory and research.

I have always felt that one of the most important roles that a book chapter can fulfill is effectively setting the stage for future scholars to build on the content of the chapter. This is a particularly important task where doctoral students are concerned, given their status as newcomers to organizational research. Ideally a doctoral student can pick up tips in a book chapter that will facilitate her or him conducting better studies than if s/he had never read the chapter.

The purpose of this paper is to examine the effects of generic medicine competition on the market share growth and pricing of originator brand medicine in the South African private pharmaceutical market.

Regression analysis is applied to market share data of originator brand drugs that have been exposed to competition from generic substitutes, based on an agency model of the prescribing physician, the pharmacist or the medical scheme.

The results indicate that the price of an originator brand medicine relative to the weighted average price of its generics has a significant negative impact on the change of its market share. Investigations into the prices of the originator brands, in relation to the number of generic equivalents in the market, indicate that the number of generics available in a specific market has a significant positive impact on the relative price of originators, thereby making originators relatively more expensive compared to their generic competitors. At the same time, the results show that the absolute price of the originator brand medicines declines as the number of generic equivalents in the market increases.

The results indicate that, for all modules pooled together, the relative price of the originator product to that of the generic equivalent, is responsible for a significant reduction in the relative change in the market share of the originator medicine. When analysed on the level of anatomical class, or the individual molecule, results are not consistent. For affordable healthcare, the results support the reduction in barriers to entry for generic medicine. Furthermore, the results support education and incentives for doctors, pharmacists and end‐users to develop generic alternatives as trusted brands in their own right.

This study quantitatively assesses the effect that generic medicine competition exerts on the market share of originator medicines in South Africa.

The purpose of this paper is to investigate the percentage of generic inventory pharmacists have in stock, to comprehend why pharmacists in Jordan recommend and dispense generic products.

In total, 104 pharmacists were surveyed using a structured questionnaire. The questionnaire contained statements about perception of generic products, inclination to recommend generic products, importance of promotions, factors influencing a recommendation, stock of generics, and among others. Correlational and discriminant analyses were used to establish associations between variables to distinguish characteristics between groups.

More than half of the Jordanian pharmacists sampled carry between 20 and 39 per cent stock of generic drugs and 46 per cent carry more than 40 per cent stock. One‐third (33 per cent) substitutes branded products by generic ones and slightly more (36 per cent) recommend more generic than branded products as opposed to those who recommend more branded products (24 per cent). Male pharmacists (49 per cent) tend to recommend more generic products than do females (24.6 per cent) and those who recommend more branded products are more influenced by sales visits rather than manufacturer's name or bonuses.

The paper provides valuable information about the pharmaceutical industry in Jordan and the empirical study adds insights from pharmacists about generic medicine.

Cheaper generic anti-retroviral medicines are encouraged and often prescribed in South Africa for HIV/AIDS treatment. However, the medicines’ acceptance rate is relatively low. This has been attributed to inadequate brand knowledge of the bioequivalence of generic medicines. Studies have examined how brand knowledge structure lead to purchase. The contributions of brand relationship builders (i.e. trust and satisfaction), which are indicators of sustainable purchase, are rarely considered. This study aims to adapt Esch, Langner, Schmitt and Geus’ (2006) brand knowledge structure and relationship model to examine the impact of South African young adults’ brand knowledge structure (brand awareness, brand image and brand beliefs) and trust on brand satisfaction and purchase.

Cross-sectional data was quantitatively collected from 207 young adults through self-administered, paper-based questionnaires. Data was analysed with structural equation modelling.

Brand awareness, image, trust and belief in efficacy positively influenced purchase. All these factors, except brand awareness, positively led to satisfaction. The tested adapted model explained 53.0 and 58.5% variances of purchase and brand satisfaction, respectively.

Considering how much brand knowledge structure and trust explained purchase and satisfaction from the tested model, South African government, pharmaceutical marketers and consumer interest groups should educate young adults about the bioequivalence, safety and efficacy of generic medicines. With greater knowledge of these qualities, satisfaction is gained from purchase decision.

Instead of the usual examination of demographic differences in generic medicine beliefs and perception, this study contributes by revealing brand-related drivers of purchase and satisfaction.